In this study, we identify DNASE1L3 as a biomarker indicative of better prognosis for patients undergoing sorafenib combined with PD-1 mAb therapy in HCC, and elucidate the mechanisms involved. The gene discussed is DNASE1L3; the disease is hepatocellular carcinoma.